Rite Aid (RAD), Walgreen (WAG) Mixed Following CVS-Cardinal Health News
Tweet
Share
E-mailGet Alerts CVS Hot Sheet
Price: $104.66 --0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.3%
Revenue Growth %: +1.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.3%
Revenue Growth %: +1.2%
Join SI Premium – FREE
CVS Caremark (NYSE: CVS) competitors Rite Aid (NYSE: RAD) and Walgreen (NYSE: WAG) are on watch as the retail pharmacy giant entered a new generic sourcing entity agreement with Cardinal Health, which is said to be the largest in the U.S.
Both companies are contributing their sourcing and supply chain expertise to this 50/50 joint venture and are committing to source generic drugs through it. n order to reflect an equitable 50/50 joint venture, the agreement includes a quarterly payment of $25 million over the life of the agreement from Cardinal Health to CVS Caremark. The payments have an estimated after-tax present value of $435 million.
While Rite Aid is slightly lower on Tuesday's trading session, Walgreen is up about 0.2 percent.
Both companies are contributing their sourcing and supply chain expertise to this 50/50 joint venture and are committing to source generic drugs through it. n order to reflect an equitable 50/50 joint venture, the agreement includes a quarterly payment of $25 million over the life of the agreement from Cardinal Health to CVS Caremark. The payments have an estimated after-tax present value of $435 million.
While Rite Aid is slightly lower on Tuesday's trading session, Walgreen is up about 0.2 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CVS Health Foundation invests $1 million in Rhode Island nonprofits tackling community health needs
- Data center strength drives Morgan Stanley’s bullish stance on this stock
- BofA is increasingly bullish on these 2 EU chip stocks
Create E-mail Alert Related Categories
Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
